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Abstract
Background: Patterns of emerging drug resistance reflect the underlying adaptive landscapes for specific drugs. In
Plasmodium falciparum, the parasite that causes the most serious form of malaria, antifolate drugs inhibit the function of
essential enzymes in the folate pathway. However, a handful of mutations in the gene coding for one such enzyme,
dihydrofolate reductase, confer drug resistance. Understanding how evolution proceeds from drug susceptibility to drug
resistance is critical if new antifolate treatments are to have sustained usefulness.
Methodology/Principal Findings: We use a transgenic yeast expression system to build on previous studies that described
the adaptive landscape for the antifolate drug pyrimethamine, and we describe the most likely evolutionary trajectories for
the evolution of drug resistance to the antifolate chlorcycloguanil. We find that the adaptive landscape for chlorcycloguanil
is multi-peaked, not all highly resistant alleles are equally accessible by evolution, and there are both commonalities and
differences in adaptive landscapes for chlorcycloguanil and pyrimethamine.
Conclusions/Significance: Our findings suggest that cross-resistance between drugs targeting the same enzyme reflect the
fitness landscapes associated with each particular drug and the position of the genotype on both landscapes. The possible
public health implications of these findings are discussed.
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Introduction
Plasmodium falciparum, the causative agent of the most virulent
form of malaria, has demonstrated an astounding ability to rapidly
evolve resistance to many different classes of drugs. Drug
resistance in malaria is thus a zealously investigated topic,
covering everything from developing methods to detect emerging
drug resistance to designing drugs that may prolong usefulness in
the face of rapidly evolving resistance. Discovering the adaptive
landscape of drug resistance provides another way to gain an
understanding of how antimalarial drug resistance evolves and
how the course of evolution is shaped by molecular forces.
One class of antimalarials, the antifolates, works by competitively
inhibiting enzymatic action in the folate pathway. Within the folate
pathway the enzymes dihydrofolate reductase (DHFR) and dihy-
dropteroate synthase (DHPS) are most often targeted for inhibition.
DHFR performs the essential task of reducing dihydrofolate to
tetrahydrofolate [1], which is a cofactor in the synthesis of purines,
pyrimidines, and amino acids [2–3]. DHPS is also a key component
in the biosynthesis of folate, producing the product 7,8-dihydrop-
teroate which immediately preceeds folate in the pathway [4].
Antifolates targeting DHFR are often combined with sulfa-drugs
aimed at DHPS and are used in combination therapies such as
sulfadoxine-pyrimethamine (SP) and trimethoprim-sulfamethoxazole
due to the synergistic properties of such combinations. The folate
pathway is an excellent drug target due to the indispensable nature of
t h ep r o d u c t so ft h ep a t h w a ya n dd u et ot h ep r e s e n c eo ff i x e d
differences in the amino acid sequencebetween parasite and host that
allow targeted inhibition of species-specific variants of DHFR. In the
case of malaria, the species-specific differences mean that adminis-
tering an antifolate drug can kill the parasite without excessive
harmful side-effects to the human host.
For decades the great efficacy, stability, and cost-effectiveness of
the antifolate pyrimethamine had made it the first-line of defense
in many developing countries plagued by malaria [5]. Regrettably,
resistance to pyrimethamine and other antifolates such as
proguanil and chlorproguanil has become widespread. While
sulfadoxine-pyrimethamine is still being used as Intermittent
Preventative Treatment (IPT) in pregnant women, although even
in IPT resistance to sulfadoxine pyrimethamine has become a
concern [6]. SP has thus been largely been replaced by artemisinin
combination therapies (ACT) in clinical settings. Antifolate
resistance is based on a handful of point mutations in pfdhfr, the
P. falciparum gene coding for dihydrofolate reductase (DHFR) that
may be compounded by concurrent resistance in DHPS (see [6]
for review of antifolate resistance).
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mutations in DHPS, are now widely observed in the field, and
pyrimethamine is fast losing efficacy as a therapeutic agent due to
this rapidly evolving drug resistance [7]. The antifolate chlorpro-
guanil is a candidate for replacing pyrimethamine in combination
therapies. In the human body chlorproguanil is metabolized into
the active compound chlorcycloguanil, which functions as a
competitive inhibitor of DHFR in a manner similar to that of
pyrimethamine. Chlorcycloguanil is a biguanide, like cycloguanil,
but possesses an additional chlorine group on the benzene ring.
Chlorproguanil was, until recently, a component in a promising
new drug combination comprising chlorproguanil-dapsone (Lap-
DapH, GlaxoSmithKline), which was withdrawn due to side-effects
associated with dapsone [8].
Chlorcycloguanil-based therapies have potent antimalarial
activity, a short half-life, and have been shown to exert decreased
selective pressure for drug-resistance when compared to pyri-
methamine [9–10], which makes them an attractive alternative to
pyrimethamine in new combination therapies [11]. However,
cross-resistance among antifolates is still of great concern and, in
the case of chlorcycloguanil and pyrimethamine, the existence of
apparent cross-resistance was described several decades ago [12]
and has also been examined more recently [13].
The molecular basis for antifolate resistance is well understood.
Specific amino acid changes at codons 16 (alanine to valine,
A16V), 51 (asparagine to isoleucine, N51I), 59 (cysteine to
arginine, C59R), 108 (serine to asparagine or threonine, S108N/
T), and 164 (isoleucine to leucine, I164L) are known to greatly
increase antifolate resistance [14–16]. Certain of these mutations
are associated with resistance to a particular antifolate. Thus
A16V in combination with S108T is associated with resistance to
cycloguanil (the active metabolite of proguanil) but not to
pyrimethamine resistance, while cross-resistance to both cyclo-
guanil and pyrimethamine is associated with alleles that include
both S108N and I164L[17]. The triple DHFR mutant S108N-
N51I-C59R is associated with sulfadoxine-pyrimethamine treat-
ment failure. Patients that are infected with parasites exhibiting the
DHFR triple mutant in combination with a DHPS double mutant
at positions 437 (alanine to glycine, A437G) and 540 (lysine to
glutamic acid, K540E) have an even higher risk for early treatment
failure than with the triple DHFR mutant alone [18].
Moreover, the laboratory findings that show genotypes
containing one or more of these mutations to confer antifolate
resistance correlate with the molecular markers associated with
resistance to one or multiple drugs in the field. Thus, in vitro studies
show that a triple mutant N51I/C59R/S108N increases resistance
to pyrimethamine 80 fold and resistance to chlorcycloguanil 40
fold [15]. In clinical settings, P. falciparum strains carrying these
same mutations (N51I/C59R/S108N) are associated with high
rates of treatment failure using sulfadoxine-pyrimethamine but
remain treatable by chlorproguanil-dapsone [19]. The addition of
a mutation of I164L to the triple mutant leads to chlorcycloguanil
resistance in addition to pyrimethamine resistance [20].
Although much is known about the genes and mutations leading
to chlorcycloguanil resistance, genetics in malaria parasites
remains technically challenging thus limiting the scope of research
possible in live parasites. The development of heterologous
expression systems for pfdhfr in yeast [21] and bacteria [22] have
allowed for more extensive research into antifolate resistance.
Using transgenic methods, novel alleles conferring drug resistance
to pyrimethamine and chlorcycloguanil have been identified by
targeted mutagenesis on pfdhfr [23–24], and novel alleles leading to
multi-drug resistance against pyrimethamine and chlorcycloguanil
have been described [25]. These systems also provide a tractable
way to examine evolution, and differences in selection pressures on
pfdhfr have been described between the antifolates pyrimethamine
and WR99210 [26].
More recent studies have sought to understand the evolutionary
trajectories that may lead to antifolate drug resistance in this
system, focusing on resistance to pyrimethamine. The evolution of
pyrimethamine resistance has been modeled at the molecular level
in yeast [27] and in a comparable system in bacteria [28]. These
studies found that pathways leading to maximum resistance are
limited, showed that some initial loss in fitness is restored by
compensatory mutations in later steps of the evolutionary process,
and implied that the withdrawal of pyrimethamine use is not likely
to restore its efficacy as a therapeutic compound.
The aim of the current study is to use the relative resistance of
mutant alleles of the pfdhfr gene to chlorcycloguanil in a yeast
system in order to explore the evolutionary landscape underlying
chlorcycloguanil resistance. We assayed all possible combinations
of 6 mutations at 5 amino acid residues (codons 16, 51, 59, 108,
and 164) and explored the evolutionary pathways accessible from
the drug-susceptible wildtype allele to strongly resistance confer-
ring mutant alleles. We also consider the implications of
chlorcycloguanil resistance in the light of known patterns of
pyrimethamine resistance caused by mutations in the same
codons.
Results
Growth rate
Of the 48 alleles constructed, 29 were viable and able to grow in
the absence of metabolic supplement (Figure 1 and Table S6 in
File S1). Previous experiments have indicated variations in growth
rate among mutant alleles of pfdhfr as expressed in a yeast system
[25][27]. Consistent with those results, growth rate analysis on our
data shows differences in growth rate among the mutant alleles in
the absence of drugs, with mutants growing both better and worse
than the wildtype strain.
There is no discernable relation between the number of
mutations in an allele and its viability (Figure 1 and Table S2 in
File S1.). The A16V change is the single most detrimental
mutation, with 16 non-viable alleles out of a possible 24 alleles
where A16V was present. Six of the eight viable alleles with an
A16V mutation also carry S108T.
IC50
Figure 1 shows the variation among IC50 values obtained for
the different alleles and how the IC50s relate to growth rate and
number of mutations. Numerical IC50 values are presented in
Table S7 in File S1. Four of the alleles proved to be highly
resistant to chlorcycloguanil. These were the quintuple mutant
11121 (A16V/N51I/C59R/S108T/I164L), the quadruple mu-
tant 10121 (A16V/C59R/S108T/I164L), and the two triple
mutants 00111 (C59R/S108N/I164L) and 10101 (A16V/C59R/
I164L). Under our experimental conditions, the high IC50 values
for chlorcycloguanil for these alleles were not significantly
different. All of these alleles do, however, show a significantly
higher IC50 than the allele ranked fifth, which is the double
mutant 10020 (A16V/S108T).
The mutation A16V, which exhibits a non-viable phenotype
when present on a wildtype background, is associated with drug
resistance on a background containing S108T, and in this
background A16V increases chlorcycloguanil resistance 10,000
fold.
In order to rank the four most highly resistant alleles for purposes
of the simulations, we estimated the IC25 and IC2 values using the
Evolution of Drug Resistance in Malaria
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for estimating the IC50s (see Table S3 in File S1). The IC2 was also
estimated independently using the linear regression values for the
slope between the two points bracketing a 2% decrease in growth
rate from the no-drug growth [24], as these values had been
explicitly measured for the relevant strains (see Table S4 in File S1).
Estimation of IC25 and IC2 values require a smaller decrease in
growth rate (25% and 2% respectively) making it a useful tool in
ranking strains that are so resistant that larger decreases in growth
rate is difficult to attain for the purpose running simulations that
require ranking. However, caution should be used in applying these
rankings for any other purpose as the small changes are necessarily
confounded by error rates that are relatively large.
Evolutionary trajectories
The 83 evolutionary trajectories that were accessible during the
simulations are summarized in Table S5 in File S1. Simulations
were run on 750 landscapes and with 100,000 rounds of evolution
on each. The top five most frequently accessed trajectories account
for approximately 80% of the probability for pathway realization,
while the top ten most often accessed trajectories make up 92% of
that probability. The landscape is multi-peaked and three
endpoints are accessible: the double mutant 10020 (A16V/
S108T), the triple mutant 00111 (C59R/S108N/I164L), and the
quintuple mutant 11121 (A16V/N51I/C59R/S108T/I164L)
(Figure 2). Pathways leading to the double mutant 10020, which
ranks fifth in IC50 overall, accounted for 7% of all realizations;
those leading to the triple mutant 00111 account for 88% of
realizations; and those leading to the quintuple mutant 11121
account for 5% of all accessible pathways. As noted, the triple
mutant 00111 and the quintuple mutant 11121 have IC50 values
that are very high and indistinguishable under our experimental
conditions, and hence the simulated evolutionary trajectories
terminate in high-IC50 alleles 93% of the time.
The single most often accessed trajectory (00000-00010-00110-
00111) is observed on all 750 landscapes, and accounts for 20% of
all realized trajectories. The most frequently followed trajectory to
the double mutant 10020 (A16V/S108T) is 00000-00020-10020,
which is followed in about 6% of simulations. The most frequently
followed trajectory to the quintuple mutant 11121 (A16V/N51I/
C59R/S108T/I164L) is 00001-00021-01021-01121-11121 and
accounts for approximately 2% of realizations.
Discussion
There is a long-standing and continuing interest in resistance to
antifolates and the level of cross-resistance observed between
different antifolates [29]. The relationship between resistance to
pyrimethamine and resistance to cycloguanil [20][15], the active
metabolite of proguanil, has been investigated, and to a lesser
extent that between pyrimethamine and chlorcycloguanil, the
active metabolite of chlorproguanil [13][9]. We use previously
published analysis of the landscape of pyrimethamine resistance
[27] along with new data on chlorcycloguanil from the current
study to analyze the underlying evolutionary landscape of drug
resistance for these compounds. Our analysis shows that, while
some alleles show increased resistance to chlorcycloguanil as well
as pyrimethamine, the adaptive landscapes underlying the
evolution of drug resistance have unique features associated with
each antifolate specifically and are not merely a function of
changes at the sequence level of the enzyme being challenged.
Common to pathways of pyrimethamine and chlorcycloguanil
resistance are the triple mutant 00111 (C59R/S108N/I164L) and
the quadruple mutant 01111 (N51I/C59R/S108N/I164L), both
of which increase resistance significantly in the presence of either
compound. In contrast, the beneficial effect of the double mutant
10020 (A16V/S108T) differs greatly in magnitude between
pyrimethamine (two fold increase) and chlorcycloguanil (10,000
fold increase). Evolutionary analysis showed that this double
mutant constitutes a fitness peak on the chlorcycloguanil
landscape, and this submaximal fitness may be reached in only
two mutational steps. In contrast, 10020 is an allele on the
pyrimethamine landscape that is so rarely traversed that it does
not show up in simulations. This example serves to illustrate the
importance of understanding not just the genetic basis of
resistance, but also the fitness landscape in the presence of a
particular selective agent, in this case the specific antifolate drug.
Looking at practical applications of doing such simulations for
more than one drug, one could imagine using genotypic
information of the alleles currently present in parasites infecting
a patient (or at alleles present the population level) and establishing
Figure 1. This heatmap indicates the relationship between the
number of amino acid replacements, growth rate in the
absence of drug (at an OD of 600 nm) and drug resistance
(IC50). Genotypes are indicated on the left hand side. No clear
correlation is seen between the number of mutations and growth rate
or resistance.
doi:10.1371/journal.pone.0019636.g001
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are being considered. In other words, in a scenario where
chlorcycloguanil has been the major selective force and the
presence of the 10020 allele has led to strong drug resistance,
pyrimethamine would still be effective. However, if chlorcyclo-
guanil resistance is conferred by amino acid substitutions of the
00111 type, the occurrence of a single mutation to 01111 would
render both drugs ineffective. Of course, further systematic
corroboration with clinical data is necessary before this scenario
can safely determine care for human patients, but the possibility
for the eventual fruitful application of in vitro resistance assays and
in silico landscape simulation certainly exists.
Interestingly, all four of the alleles with the highest IC50s
include the I164L mutation. The addition of I164L on certain
backgrounds is associated with as much as a 1000-fold increase in
resistance to antifolates, including chlorcycloguanil [25]. In the
field, I164L is associated with the majority of treatment failures
that occur when using a chlorcycloguanil combination therapy
[30][31][18]. I164L is known to be a late arising mutation in the
emergence of drug resistance in clinical settings, where the more
widely used pyrimethamine is likely to have played a much greater
role in shaping the evolution of drug resistance than the less
ubiquitously used chlorcycloguanil. Looking at I164L as a
component of mutational trajectories, it occurs as the first step
in only 2% of trajectories on the pyrimethamine landscape [27]
which is congruent with the relative scarcity of this mutation in
natural settings as a responcse to pyrimethamine drug pressure.
However, 14% of trajectories (leading to both the 00111 and
11121 peaks) on the chlorcycloguanil landscape have I164L as a
first step. This finding underscores the importance of the I164L
mutation in leading to high-level resistance to chlorcycloguanil
specifically.
Our findings further demonstrate that, based on the chlorcy-
cloguanil landscape in yeast, I164L is not necessarily a late arising
mutation. This likely reflects a fundamental difference between the
adaptive landscapes for pyrimethamine and chlorcycloguanil and
underscores the importance of drug specific patterns of evolution.
Simultaneously we recognize that I164L may not be as readily
found as a single mutation in nature due to some additional fitness
deficit that is not related to selection by pyrimethamine use but
which we cannot determine in this context. It has already been
observed that early mutations may entail some loss of fitness under
a regime where no drug pressure is present but fitness is later
restored by compensatory mutations [28]. Trajectories containing
I164L as an initial step seem to follow such a pattern. An
important observation is gained from the startling presence of
I164L among the initial mutational steps found on among many
trajectories. That is, the probability of evolutionary trajectories
and the order of the steps that make up those trajectories can be
heavily influenced by differences in the underlying landscape
based on the drug treatment used.
The second most often accessed endpoint is the quintuple
mutant 11121 (A16V/N51I/C59R/S108T/I164L), an allele not
generally observed in clinical settings. Conceivably this may simply
be due to a smaller sample size for alleles associated with
chlorcycloguanil resistance. Chlorcycloguanil is not and has not
Figure 2. The top ten most often realized evolutionary trajectories. The trajectories move from the wildtype allele (00000) to one of three
endpoints (00111, 10020, or 111121) in steps of one mutation at a time. The percentage of trajectories that lead to each endpoint is indicated. The
genotype 00111 is the endpoint of the majority of trajectories.
doi:10.1371/journal.pone.0019636.g002
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available on resistance mutations in the field apart from clinical
trials. However, there are also intrinsic explanations for this
observation. As two more mutations are required to reach this
allele, it may be expected to occur more infrequently than a triple
mutant given that mutations at all positions are equally likely.
Alternatively, the relative dearth of pathway realizations leading to
the quintuple mutant 11121 may be a reflection of the negative
interaction between the mutations found in this allele. This allele
contains the mutation S108T, which is much more rarely observed
than S108N and usually occurs in combination with A16V [32]. It
has already been noted that alleles containing A16V are often non-
viable although some are rescued by the addition of S108T.
The order in which mutations occur may thus play a critical role
in determining whether a particular path leading to 11121 is
accessible by evolution, or whether a fitness valley makes this
trajectory impassable. Accessing a path of increasing resistance to
the triple mutant 00111 (C59R/S108N/I164L) does not have the
same problem, as this allele contains mutations that ’’mix’’ much
better. Due to the effect of such epistatic interactions there may be
a more limited number of viable alleles available as options when
traversing the landscape from 00000 to 11121.
Interestingly, 10121 (A16V/C59R/S108T/I164L) and 10101
(A16V/C59R/I164L) exhibit high IC50s, indistinguishable from
those of the triple mutant 00111 (C59R/S108N/I164L) and the
quintuple mutant 11121 (A16V/N51I/C59R/S108T/I164L), but
these alleles are not accessed as endpoints in the simulations. In the
case of 10121 this is probably due to the adjacency in sequence
space of the quintuple mutant 11121, which was assigned a higher
rank based on our estimations. However, in all our simulations,
10101 (A16V/C59R/I164L) appears only once, and then as an
intermediate step on a pathway leading to 11121 (00000-00100-
00101-10101-10121-11121). Unlike the alleles on the more
frequently traversed pathways to the fitness peak at 00111
(C59R/S108N/I164L), the allele 10101 is not one generally
found in clinical settings. The trajectory analysis thus shows that
the absence of this allele in nature is likely due to the unfavorable
location of this point in sequence space, having both a low
probability of realization and not occurring as the end point to a
pathway, rather than due to higher susceptibility to drug
treatment.
Cycloguanil-resistant/pyrimethamine-sensitive parasites have
emerged in clinical settings [16]. In our data, the double mutant
10020 (A16V/S108T) shows how that situation can arise. The
10020 allele is a fitness peak on a landscape of resistance to
chlorcycloguanil. However, a strain that evolves to the 10020
double mutant in response to selection by chlorcycloguanil would
be susceptible to pyrimethamine.
The results of the evolutionary trajectory analysis further
complement studies showing incomplete cross-resistance between
chlorcycloguanil and pyrimethamine. In an in vitro study of P.
falciparum field isolates, cross-resistance existed between pyrimeth-
amine and chlorcycloguanil and the triple mutant (S108N/C59R/
N51I or 01110) increased resistance to the drugs 225-fold and 48-
fold, respectively [13]. While in vitro the presence of this triple
DHFR mutant at codons 108, 51, and 59 (combined with a double
DHPS mutant) increased drug resistance to both antifolates, this
combination of mutations was only associated with clinical
treatment failure with sulfadoxine-pyrimethamine but not with
chlorproguanil-dapsone [18]. The addition of the I164L mutation
results in clinical failure of chlorproguanil-based therapies.
In 1968 a study of the parasite P. berghei in mice showed that
there is some cross-resistance between parasites exposed to
chlorcycloguanil and pyrimethamine, with exposure to chlorcy-
cloguanil inducing broader resistance than pyrimethamine [33]. It
was clear then that certain resistant strains may be countered by
using a different drug targeting the same mutant enzyme, but that
multiply resistant lines may also arise. Tracing the mutational
trajectories of those two drugs now affords an evolutionary
explanation for those results from many decades ago: The shape of
the underlying adaptive landscapes of the drugs in question affects
the genotypes (and thus phenotypes) that will emerge—even
between drugs targeting the same enzyme in the same manner.
Drug resistance is a major factor in determining the course of
treatment for malaria and other infectious diseases. The ability to
not only pinpoint mutations that lead to drug resistant phenotypes,
but also to predict the route evolution is most likely to take once
drug pressure is exerted, are invaluable assets in preserving the
efficacy of chemotherapy.
Knowledge regarding the progression of evolutionary trajecto-
ries can be determined in an in vitro system in a relatively short
period of time as compared to tracking trends in the field.
Scientists and clinicians may then have advance notice of the
mutational progression in trajectories that are likely to lead to the
exhibition of high drug resistance allowing them to use their
limited resources in a more focused way as they survey for the
emergence of drug resistance. Transgenic systems such as the one
used in this study cannot address all the complexities involved in
the evolution of drug resistance in clinical settings. An adaptive
landscape established in a yeast system may thus not directly apply
to natural populations of P. falciparum. Rather it provides a
tractable way of exploring the processes governing patterns and
constraint of drug evolution in nature and serves to inform further
studies in the field.
Materials and Methods
Construction of yeast strains
Yeast dhfr knockout strains may be rescued by replacing the
endogenous yeast gene with the P. falciparum gene. This creates a
yeast strain that is sensitive to antimalarial drugs targeting DHFR
and thus allows the study of the impact of mutations on drug
sensitivity in a tractable manner. Genetic manipulation and drug
resistance assays in P. falciparum remains technically challenging
and thus in vitro experimentation can be very valuable if we keep in
mind that this heterologous system may not in all cases accurately
reflect the in vivo system. The construction of the Saccharomyces
cerevisiae TH5 (MATa leu2-3,112 trp1 ura3-52 dfr1::URA3 tup1)
strains containing mutant Plasmodium falciparum dhfr (pfdhfr) alleles is
described in detail elsewhere [27]. Briefly, all 48 combinations of
six mutations at five amino acid coding sites (Table S6 in File S1)
in the dhfr gene of P. falciparum were constructed on the same
genetic background using site-directed mutagenesis (QuikChange
Site-Directed Mutagenesis Kit, Stratagene, Cedar Creek TX).
Mutations were confirmed by sequencing. We transformed the
yeast with each of the 48 alleles on a shuttle vector using the EZ
Yeast Transformation Kit (Zymo, Orange CA). The presence of
the GR7 vector was selected for by growing transformed colonies
on tryptophan dropout media (SC trp
2). The GR7 shuttle vector
and the TH5 strain of S. cerevisiae were generously provided by
Carol Sibley and were specifically engineered for use in in vitro
assays to study antifolate resistance in Plasmodium [21].
Growth rate and drug resistance assays
Growth rates and drug resistance assays were conducted as
described previously [27] with the following alterations: After
growing overnight at 30uC in 5 mL liquid YPD, colonies were
diluted to an OD of 0.1 at 600 nm and then inoculated into
Evolution of Drug Resistance in Malaria
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19636200 mL YPD containing chlorcycloguanil at concentrations of
0M ,1 0
28 M, 10
27 M, 10
26 M, 10
25 M, and 10
24 M each.
Chlorcycloguanil was diluted in ethanol to a final concentration of
1% ethanol. Chlorcycloguanil was generously provided by Jacobus
Pharmaceuticals (Princeton, NJ). Growth rate and resistance
experiments were conducted on a Bioscreen C microbiological
workstation (Thermo Labsystems). Growth rates were measured
by spectrophotometry at 600 nm at 30uC in 15 minute increments
over a period of 72 hr.
IC50 and calculation of evolutionary trajectories
The half-maximal inhibitory concentration (IC50) for each
strain was determined using non-linear regression analysis in the
open-source statistical environment R [34] using the method
described in [27]. We used previously established methodology to
determine the evolutionary trajectories that are accessible for
DHFR evolution to attain resistance to chlorcycloguanil [35]
[36][27].
Our evolutionary model assumes that the time between
mutations arising is much longer than the time to loss or fixation
of new mutations, which allows the fixation of at most one
mutation during each interval of time. At each interval, all
mutational neighbors that will result in an increase in fitness are
considered, including reversion to a previously fixed mutation
[36]. It is assumed that the probability of fixation for beneficial
mutations greatly outweighs that of deleterious or even neutral
mutations, such that deleterious or neutral mutational fixations
may be safely ignored in the presence of a possible beneficial
mutation (see [27]) for complete details of this model).
We simulated landscapes and trajectories in this manner as it
allows the probability estimates to account for uncertainty in our
resistance measurements. Many trajectories thus occur on
landscapes that have low-probabilities, i.e. the landscape itself
has a low likelihood of realization. We therefore only report a
consensus of trajectories that occur on at least 85% of landscapes.
Doing so allows us to identify the strongest trends which is
appropriate as in an in vitro system where some intricacies of in vivo
systems may not be discernable but strong and important effects
may still be observed in well planned experiments.
Using the IC50 values for the different mutant alleles, we ran
computer simulations to determine the evolutionary trajectories
most often accessed. Each initial condition consisted of a fitness
landscape constructed by choosing a set of IC50 values, one for
each genotype, by sampling one value at random from a normal
distribution with the same mean and variance of IC50 as estimated
for each genotype. For each of 750 such fitness landscape so
constructed, 10
5 independent computer simulations yielding a
complete mutation-selection trajectory were carried out.
Supporting Information
File S1 This chart shows the growth rates of all viable alleles in
the absence of drug. The growth rates were determined by
measuring cell density at OD600.
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